Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Positron emission tomography in thyroid cancer management.

Larson SM, Robbins R.

Semin Roentgenol. 2002 Apr;37(2):169-74. Review.

PMID:
12134369
2.

Positron emission imaging of head and neck cancer, including thyroid carcinoma.

Schöder H, Yeung HW.

Semin Nucl Med. 2004 Jul;34(3):180-97. Review.

PMID:
15202100
3.

Role of 18F-FDG-PET and PET/CT imaging in thyroid cancer.

Nanni C, Rubello D, Fanti S, Farsad M, Ambrosini V, Rampin L, Banti E, Carpi A, Muzzio P, Franchi R.

Biomed Pharmacother. 2006 Sep;60(8):409-13. Epub 2006 Aug 1. Review.

PMID:
16891093
4.

Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer.

Finkelstein SE, Grigsby PW, Siegel BA, Dehdashti F, Moley JF, Hall BL.

Ann Surg Oncol. 2008 Jan;15(1):286-92. Epub 2007 Sep 20.

PMID:
17882493
5.

[F-18-fluordeoxyglucose positron emission tomography on patients with differentiated thyroid cancer who present elevated human serum thyroglobulin levels and negative I-131 whole body scan].

Ruiz Franco-Baux JV, Borrego Dorado I, Gómez Camarero P, Rodríguez Rodríguez JR, Vázquez Albertino RJ, Navarro González E, Astorga Jiménez R.

Rev Esp Med Nucl. 2005 Jan-Feb;24(1):5-13. Spanish.

6.
7.

Positron emission tomography of the thyroid, with an emphasis on thyroid cancer.

McDougall IR, Davidson J, Segall GM.

Nucl Med Commun. 2001 May;22(5):485-92. Review.

PMID:
11388568
8.

PET imaging in differentiated thyroid cancer: where does it fit and how do we use it?

Hall NC, Kloos RT.

Arq Bras Endocrinol Metabol. 2007 Jul;51(5):793-805. Review.

9.
10.

FDG-PET in head and neck, and thyroid cancer.

Macapinlac HA.

Chang Gung Med J. 2005 May;28(5):284-95.

11.

Positron emission tomography (18FDG-PET) in the detection of medullary thyroid carcinoma metastases.

Mucha SA, Kunert-Radek J, Pomorski L.

Endokrynol Pol. 2006 Jul-Aug;57(4):452-5.

PMID:
17006852
12.

18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.

Sperti C, Bissoli S, Pasquali C, Frison L, Liessi G, Chierichetti F, Pedrazzoli S.

Ann Surg. 2007 Dec;246(6):932-7; discussion 937-9.

PMID:
18043094
14.

Review. 18F-FDG PET in the diagnosis and follow-up of thyroid malignancy.

Al-Nahhas A, Khan S, Gogbashian A, Banti E, Rampin L, Rubello D.

In Vivo. 2008 Jan-Feb;22(1):109-14. Review.

15.

PET/CT: will it change the way that we use CT in cancer imaging?

Hicks RJ, Ware RE, Lau EW.

Cancer Imaging. 2006 Oct 31;6:S52-62.

16.

Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer.

Thrall MM, DeLoia JA, Gallion H, Avril N.

Gynecol Oncol. 2007 Apr;105(1):17-22. Epub 2007 Jan 10.

PMID:
17208284
17.

Diagnostic accuracy and prognostic value of 18F-FDG PET in Hürthle cell thyroid cancer patients.

Pryma DA, Schöder H, Gönen M, Robbins RJ, Larson SM, Yeung HW.

J Nucl Med. 2006 Aug;47(8):1260-6.

18.

Comparison between positron emission tomography using 2-[fluorine-18]fluoro-2-deoxy-D-glucose, conventional imaging and computed tomography for staging of breast cancer.

Mahner S, Schirrmacher S, Brenner W, Jenicke L, Habermann CR, Avril N, Dose-Schwarz J.

Ann Oncol. 2008 Jul;19(7):1249-54. doi: 10.1093/annonc/mdn057. Epub 2008 Mar 19.

19.

The role of FDG PET in management of neck metastasis from head-and-neck cancer after definitive radiation treatment.

Yao M, Smith RB, Graham MM, Hoffman HT, Tan H, Funk GF, Graham SM, Chang K, Dornfeld KJ, Menda Y, Buatti JM.

Int J Radiat Oncol Biol Phys. 2005 Nov 15;63(4):991-9. Epub 2005 Aug 15.

PMID:
16099601
20.
Items per page

Supplemental Content

Write to the Help Desk